Three group members presented their research at the ACS Fall 2021 meeting. Undergraduate Wesley McDonald presented a poster Toward Hypoxia Active Ru(II) Complexes for Cancer Phototherapy, grad student Houston Cole gave a talk Synthesis, Characterization, and Evaluation of a New Class of Metal Complex Photosensitizers, and post-doc Elam Ramasamy gave…
Houston Cole and the lab’s work were featured in an article in the Dallas Morning News.
Wesley McDonald is featured in a UTA news item about our research.
John Roque passed his defense today and can now very deservedly append Ph.D. to his name. Great work, John!
We are pleased to announce that a new graduate student Gurleen Kaur has joined our group!
Congratulations to Houston for passing his proposal defense!
We are very excited that Ge Shi has moved to Texas to rejoin our group as a research associate!
180 days post single treatment results: 45% complete response, 22% partial response, 11% no response, 22% yet undetermined (n=11). Taken from the Theralase 2020Q4 newsletter.
The McFarland Group is happy to welcome our newest post doc Dr. Elamparuthi Ramasamy to the lab!
The U.S. Food and Drug Administration has granted Fast Track Designation to the Phase II Non-Muscle Invasive Bladder Cancer clinical study, opening the possibility of an Accelerated Approval and Priority Review. More details can be found at the Theralase press release.